Navigation Links
Veracyte Appoints Mark Spring as Chief Financial Officer
Date:1/31/2012

any's continued commercial growth and the development of additional genomic tests that serve unmet clinical needs in other disease areas."

About the Afirma Thyroid FNA Analysis
Veracyte's Afirma Thyroid FNA Analysis is designed to improve thyroid nodule diagnosis. This novel solution combines expert cytopathology assessment of thyroid nodule fine needle aspiration (FNA) samples with the company's Afirma Gene Expression Classifier, a genomic test used to clarify inconclusive results as benign or suspicious for cancer, and thus help patients avoid unnecessary surgery if their nodules are actually benign. Two independent clinical studies have shown that the Afirma Gene Expression Classifier can reclassify patients with indeterminate thyroid FNA results as "benign" with the same degree of accuracy as a benign cytopathology diagnosis.

Thyroid cancer is the fastest-growing cancer in the U.S., with an estimated 56,460 new cases expected in 2012, according to the American Cancer Society. An estimated 450,000 thyroid nodule fine needle aspirations (FNAs) – a minimally invasive procedure to extract suspicious cells for examination under a microscope – are performed in the U.S. each year to rule out cancer. Thyroid nodule FNAs are challenging to interpret, however, producing ambiguous results in up to 30 percent of cases. Current guidelines recommend that most of these patients undergo thyroid resection for a definitive diagnosis, given that thyroid cancer is highly treatable. Post-surgical results, however, show that only 20-30 percent of these patients have cancer.

About Veracyte
Veracyte, Inc., based in South San Francisco, Calif., is pioneering the emerging field of molecular cytology, applying molecular biomarkers to cytology samples in order to improve disease diagnosis by clarifying indeterminate results obtained from current methods. The company aims to enable doctors to make more informed treatment decisions that
'/>"/>

SOURCE Veracyte, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Veracyte Announces Medicare Coverage for Its Afirma® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis
2. New Data Suggest Veracytes Afirma® Gene Expression Classifier Cost-Effectively Resolves Inconclusive Thyroid Nodule FNA Biopsy Results
3. New Data Suggest Veracytes Molecular Test Improves Accuracy of Thyroid Nodule Diagnosis Using Fine Needle Aspirate (FNA) Samples
4. MAP Pharmaceuticals Appoints W. James OShea to Board of Directors
5. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
6. PuraMed BioScience, Inc. Appoints Sue A. Baacke, CPA, as CFO
7. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
8. Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
9. BioStorage Technologies Appoints New Member to Board of Directors
10. Hybrid Fuels, Inc. Appoints Industry Expert as New CEO
11. Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... CA (PRWEB) June 18, 2013 (PRWEB) June 18, ... #1 time and attendance system in North America, ... that shares employee data and payroll records between ... AccountLinx Plus automates ExakTime software setup and ... software imports employee data from a business’ current ...
(Date:6/18/2013)... Phoenix, AZ (PRWEB) June 18, 2013 ... the 2013 Innovation Challenge Winner out of hundreds of ... in its spring Arizona Innovation Challenge . The ... the country for a technology commercialization challenge, granting a ... world’s most promising technology ventures. Nasseo’s state of the ...
(Date:6/18/2013)...  AMRI (NASDAQ: AMRI ) announced ... , site has received approval to expand its ... handle Schedule 2 and 2N controlled substances. The ... Burlington,s physical security and quality systems, ... http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) With its ...
(Date:6/18/2013)... , June 18, 2013 ... has announced the addition of the report ... Companies " to their offering. ... briefly reviews basics of human genome variations, ... Current large and small sequencers are described ...
Breaking Biology Technology:ExakTime Introduces AccountLinx Plus 2Nasseo Named 2013 Innovation Challenge Winner by Arizona Commerce Authority 2AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2DNA Sequencing: Technologies, Markets and Companies - 2013 Report 2
... Cardium Therapeutics (NYSE Amex: CXM ) today ... the U.S. Food and Drug Administration (FDA) seeking marketing ... Excellagen XL is an advanced wound care management ... designed for use by physicians in patients with topical ...
... DUBLIN, Ireland, November 2 The Board of,Directors of ... Mr David,Stout joined the Board as a Non Executive Director ... Mr Stout has extensive pharmaceutical experience. Most recently he was,President, ... pharmaceutical operations in the United States, Europe,Japan and all other ...
... successful phase III trial points to the first new lupus ... 2 The Lupus Research Institute (LRI) and its National ... Sciences (HGS) and GlaxoSmithKline for achieving an historical landmark - ... the first successfully tested new drug developed specifically for people ...
Cached Biology Technology:Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 2Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 3Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 4New Shire Board Member 2Lupus Research Institute: Benlysta(TM) Trial Results in an Historic Research Breakthrough and Victory for People With Lupus 2
(Date:6/17/2013)... foundations with more modern elements. Using this same approachbut ... Dietrich School of Arts and Sciences have designed a ... storage, and gas transport more efficient and at a ... issue of the Journal of the American Chemical ... builds upon Pitt Associate Professor of Chemistry Nathaniel Rosi,s ...
(Date:6/17/2013)... The AGA Research Foundation and Horizon Pharma further ... gastroenterology with the 2013 AGA-Horizon Pharma Fellow Abstract Prizes ... "In its third year, this competition continues to grow ... promising careers in basic and clinical research," said Nicholas ... Foundation. "We are extremely proud of all that these ...
(Date:6/16/2013)... programs for female sex workers in India reduce rates ... a University of Toronto study has found. ... mostly in the southern states of Andhra Pradesh, Karnataka, ... Prabhat Jha from U of T,s Dalla Lana School ... Global Health Research (CGHR), examined the impact of prevention ...
Breaking Biology News(10 mins):'Chemical architects' build materials with potential applications in drug delivery and gas storage 2Horizon Pharma Abstract Prizes recognize promising fellows and students 2HIV prevention among female sex workers in India reduces HIV and syphilis 2
... and the environment will gather in Nairobi, Kenya this ... cycle of drought and food insecurity. The Beating Famine ... the Sahel region of Africa, this time through Niger, ... will take place on April 10-13 at the World ...
... 2012 The Canadian Journal of Cardiology ... Society,s atrial fibrillation guidelines. Atrial fibrillation is the ... stroke, illness in general, and death. It is, for example, ... year has seen important changes in the drugs available to ...
... known for its role in embryonic development and cancer ... or scleroderma, therapy. The finding, discovered by a cross-disciplinary ... Hughes Distinguished Professor of Rheumatology at Northwestern University Feinberg ... Arthritis & Rheumatism. "We showed, for ...
Cached Biology News:Beating famine: Sustainable food security through land regeneration in a changing climate 2New genetic path for scleroderma 2
... 3.1.21.1) is a nonspecific endonuclease that degrades ... by hydrolyzing phosphodiester linkages, producing mono and ... group. Ambion's RNase-free DNase I is of ... to degrade DNA in the presence of ...
Rabbit polyclonal antibody to Neuromedin U Receptor 1 (GPR66)...
... Perhaps sheer in-house demand is causing ... want your precious antibody. This can cause ... • Receive royalties for your hard ... and let us build it up and ...
... (rat) - Diluted Antiserum for RIA, Host: ... U-23 (rat) Immunology Products, Host: Rabbit ... our corresponding peptide and 1 ... Neuromedin U-23 (rat) (H-9295) and ([ 1 ...
Biology Products: